- Home
- ARTV vs PEPG Comparison
ARTV vs PEPG Comparison
Compare ARTV & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- PEPG
- Stock Information
- Founded
- ARTV 2019
- PEPG 2018
- Country
- ARTV United States
- PEPG United States
- Employees
- ARTV N/A
- PEPG N/A
- Industry
- ARTV
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- ARTV
- PEPG Health Care
- Exchange
- ARTV NYSE
- PEPG Nasdaq
- Market Cap
- ARTV 39.0M
- PEPG 45.5M
- IPO Year
- ARTV 2024
- PEPG 2022
- Fundamental
- Price
- ARTV $1.61
- PEPG $1.28
- Analyst Decision
- ARTV Strong Buy
- PEPG Buy
- Analyst Count
- ARTV 8
- PEPG 3
- Target Price
- ARTV $18.14
- PEPG $7.67
- AVG Volume (30 Days)
- ARTV 303.9K
- PEPG 290.3K
- Earning Date
- ARTV 08-28-2025
- PEPG 08-07-2025
- Dividend Yield
- ARTV N/A
- PEPG N/A
- EPS Growth
- ARTV N/A
- PEPG N/A
- EPS
- ARTV N/A
- PEPG N/A
- Revenue
- ARTV N/A
- PEPG N/A
- Revenue This Year
- ARTV N/A
- PEPG N/A
- Revenue Next Year
- ARTV N/A
- PEPG N/A
- P/E Ratio
- ARTV N/A
- PEPG N/A
- Revenue Growth
- ARTV N/A
- PEPG N/A
- 52 Week Low
- ARTV $1.47
- PEPG $0.88
- 52 Week High
- ARTV $17.31
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- PEPG 41.13
- Support Level
- ARTV N/A
- PEPG $1.05
- Resistance Level
- ARTV N/A
- PEPG $1.49
- Average True Range (ATR)
- ARTV 0.00
- PEPG 0.10
- MACD
- ARTV 0.00
- PEPG -0.02
- Stochastic Oscillator
- ARTV 0.00
- PEPG 38.64
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.